Hotel Palace Berlin Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2018
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
21st-Century Drug Discovery and Development for Global Health (S3)
Organizer(s) Ken Duncan, Elizabeth Winzeler and Lluís Ballell
October 17—20, 2018
Hotel Palace Berlin • Berlin, Germany
Discounted Abstract Deadline: Jun 19, 2018
Abstract Deadline: Jul 17, 2018
Scholarship Deadline: Jun 19, 2018
Discounted Registration Deadline: Aug 16, 2018
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation
Summary of Meeting:
Infectious diseases cause substantial morbidity and mortality in the developing world. The medicines available today are often inconvenient to use or result in side effects, and many are being lost to emerging drug resistance. There remains an urgent need to discover and develop the next generation of transformative medicines that are more efficacious, more highly targeted, and have a better safety profile. This will only be achieved through the application of state-of-the-art drug discovery tools, technologies and approaches. This meeting will focus on diseases caused by parasitic organisms and bacteria, including malaria, neglected tropical diseases, diarrheal disease and tuberculosis. The goals of this meeting are to improve understanding of the disease burden and challenges faced in developing new therapies, to highlight examples of progress towards new drug candidates, and to foster communication and collaboration among communities of researchers working in global health across the spectrum from research to the clinic. The meeting will be of interest to basic scientists as well as drug discovery and development experts wanting to gain a better understanding of the challenges and opportunities in global health.
View Scholarships/Awards
Infectious diseases cause substantial morbidity and mortality in the developing world. The medicines available today are often inconvenient to use or result in side effects, and many are being lost to emerging drug resistance. There remains an urgent need to discover and develop the next generation of transformative medicines that are more efficacious, more highly targeted, and have a better safety profile. This will only be achieved through the application of state-of-the-art drug discovery tools, technologies and approaches. This meeting will focus on diseases caused by parasitic organisms and bacteria, including malaria, neglected tropical diseases, diarrheal disease and tuberculosis. The goals of this meeting are to improve understanding of the disease burden and challenges faced in developing new therapies, to highlight examples of progress towards new drug candidates, and to foster communication and collaboration among communities of researchers working in global health across the spectrum from research to the clinic. The meeting will be of interest to basic scientists as well as drug discovery and development experts wanting to gain a better understanding of the challenges and opportunities in global health.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
The meeting will begin on Wednesday, October 17 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Saturday, October 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Sunday, October 21 in order to fully experience the meeting.
WEDNESDAY, OCTOBER 17
THURSDAY, OCTOBER 18
FRIDAY, OCTOBER 19
SATURDAY, OCTOBER 20
SUNDAY, OCTOBER 21
Conference Program Print | View meeting in 12 hr (am/pm) time
The meeting will begin on Wednesday, October 17 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Saturday, October 20 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Sunday, October 21 in order to fully experience the meeting.
WEDNESDAY, OCTOBER 17
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.
08:00—09:50
New Therapeutics for Global Health
Meeting has ended...abstracts no longer viewable online.
*
Ken Duncan,
Bill & Melinda Gates Foundation, USA
Nathalie Strub Wourgaft,
Drugs for Neglected Diseases Initiative, DNDi, Switzerland
Transformative New Therapies for Human African trypanosomiasis
Transformative New Therapies for Human African trypanosomiasis
Thierry T. Diagana,
Novartis Institute for Tropical Diseases, USA
Progress with the Clinical Development of Cipargamin (KAE609) and Ganaplacide (KAF156) for the Treatment of Malaria
Progress with the Clinical Development of Cipargamin (KAE609) and Ganaplacide (KAF156) for the Treatment of Malaria
Lluís Ballell,
GlaxoSmithKline, Spain
Global Health GSK R&D in Tres Cantos – Introducing GSK701 and GSK286 as Novel Preclinical Candidates against Malaria and TB
Global Health GSK R&D in Tres Cantos – Introducing GSK701 and GSK286 as Novel Preclinical Candidates against Malaria and TB
Joseph D. Turner,
Liverpool School of Tropical Medicine, UK
Short Talk: Novel Anti-Wolbachia Drugs as Short-Course Macrofilaricides for Onchocerciasis
Short Talk: Novel Anti-Wolbachia Drugs as Short-Course Macrofilaricides for Onchocerciasis
10:10—12:00
Robust Target Validation – What Does it Mean?
Meeting has ended...abstracts no longer viewable online.
*
Anil Koul,
Institute of Microbial Technology, India
Elizabeth A. Winzeler,
University of California, San Diego, USA
Multidisciplinary Approaches to the Discovery of Chemoprotective Drugs and Targets for Malaria
Multidisciplinary Approaches to the Discovery of Chemoprotective Drugs and Targets for Malaria
Dirk Schnappinger,
Weill Cornell Medical College, USA
Combining Chemical Probes and Genetic Knockdowns to Validate Drug Targets in Mycobacterium tuberculosis
Combining Chemical Probes and Genetic Knockdowns to Validate Drug Targets in Mycobacterium tuberculosis
Boris Striepen,
University of Pennsylvania, USA
Using Molecular Genetics to Understand and Combat Cryptosporidium
Using Molecular Genetics to Understand and Combat Cryptosporidium
Andrew Fraser,
University of Toronto, Canada
Short Talk: Dissecting the Pathway for Rhodoquinone Biosynthesis in C. elegans: It all Starts at the Beginning
Short Talk: Dissecting the Pathway for Rhodoquinone Biosynthesis in C. elegans: It all Starts at the Beginning
13:30—16:00
Joint Keynote Session and Panel Discussion with Grand Challenges: Innovation in Drug Discovery
Keynote
Ken Duncan, The Bill & Melinda Gates Foundation, USA
Spotlight Talk
Kelly Chibale, University of Cape Town, South Africa
Panel Discussion: Combatting Antimicrobial Resistance through Drug Discovery and Innovation
*Sally Davies, UK Department of Health, UK
Stephen Baker, University of Oxford, UK
Renu Swarup, Department of Biotechnology, India
Closing Keynote
Lynda Stuart, The Bill & Melinda Gates Foundation, USA
Ken Duncan, The Bill & Melinda Gates Foundation, USA
Spotlight Talk
Kelly Chibale, University of Cape Town, South Africa
Panel Discussion: Combatting Antimicrobial Resistance through Drug Discovery and Innovation
*Sally Davies, UK Department of Health, UK
Stephen Baker, University of Oxford, UK
Renu Swarup, Department of Biotechnology, India
Closing Keynote
Lynda Stuart, The Bill & Melinda Gates Foundation, USA
16:00—17:00
Networking and Welcome Mixer with Grand Challenges and Keystone Symposia
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:00
Importance of Chemical Diversity in Seeking New Leads
Meeting has ended...abstracts no longer viewable online.
*
Courtney Cortez Aldrich,
University of Minnesota, USA
Xiaopeng Bai,
GlaxoSmithKline, USA
Experience with DNA-Encoded Libraries in Search for New Leads against TB
Experience with DNA-Encoded Libraries in Search for New Leads against TB
E. Paige Stout,
Sirenas, USA
Sirenas Biochemometrics Platform: Transforming the Search for New Medicines
Sirenas Biochemometrics Platform: Transforming the Search for New Medicines
Coffee Break
Judy A. Sakanari,
University of California, San Francisco, USA
Identifying Anti-Filarial Candidates using a Multifaceted Screening Funnel
Identifying Anti-Filarial Candidates using a Multifaceted Screening Funnel
Charles E. Mowbray,
Drugs for Neglected Diseases Initiative, Switzerland
A New Era of Orally Active Treatments for Leishmaniasis Patients
A New Era of Orally Active Treatments for Leishmaniasis Patients
Jennifer Elizabeth Collins,
University of Central Florida, USA
Short Talk: Novel Antiplasmodial Compounds from Fungi
Short Talk: Novel Antiplasmodial Compounds from Fungi
17:00—19:00
Alternative Approaches to Drug Delivery – Opportunities and Challenges
Meeting has ended...abstracts no longer viewable online.
*
Anna Upton,
TB Alliance, USA
Paul L. Feldman,
Intarcia Therapeutics, USA
Application of the Intarcia Medici Drug Delivery SystemTM for Long-Acting HIV Prevention for Global Health
Application of the Intarcia Medici Drug Delivery SystemTM for Long-Acting HIV Prevention for Global Health
Andrew Martin Bellinger,
Lyndra, USA
Development of Oral, Ultra Long-Lasting, Sustained Release Therapies in the Fight against Malaria and HIV
Development of Oral, Ultra Long-Lasting, Sustained Release Therapies in the Fight against Malaria and HIV
Arnab Chatterjee,
Calibr, USA
Chemoprophylaxis for Prevention of Malaria Infection
Chemoprophylaxis for Prevention of Malaria Infection
Daniel Greenwood,
Francis Crick Institute, UK
Short Talk: Subcellular Antibiotic Visualisation Reveals a Dynamic Drug Reservoir in Mycobacterium tuberculosis-Infected Macrophages
Short Talk: Subcellular Antibiotic Visualisation Reveals a Dynamic Drug Reservoir in Mycobacterium tuberculosis-Infected Macrophages
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
08:00—11:15
Improving Target and Phenotypic-Based Approaches
Meeting has ended...abstracts no longer viewable online.
*
Tanya Parish,
Infectious Disease Research Institute, USA
Leann M. Tilley,
University of Melbourne, Australia
The Proteasome as a Target for New Antimalarial Drugs
The Proteasome as a Target for New Antimalarial Drugs
Kirsten Hanson,
University of Texas at San Antonio, USA
Profiling Compounds against Liver Stage Malaria
Profiling Compounds against Liver Stage Malaria
Beatriz Baragana,
University of Dundee, UK
Short Talk: Lysyl tRNA Synthetase as a Drug Target in Apicomplexan Parasites
Short Talk: Lysyl tRNA Synthetase as a Drug Target in Apicomplexan Parasites
Nyssa Drinkwater,
Monash University, Australia
Short Talk: Rational Design of a Multi-Target Antimalarial Compound with in vivo Activity
Short Talk: Rational Design of a Multi-Target Antimalarial Compound with in vivo Activity
Coffee Break
Deborah T. Hung,
Broad Institute of MIT & Harvard, USA
Multiplex Screening of an M. tuberculosis Hypomorph Library Simultaneously Identifies Lead and Target
Multiplex Screening of an M. tuberculosis Hypomorph Library Simultaneously Identifies Lead and Target
Marc Gitzinger,
BioVersys AG, Switzerland
A SMARt Approach to Reversing Drug Resistance in TB and Deploying the Hidden Potential of Current TB Drugs
A SMARt Approach to Reversing Drug Resistance in TB and Deploying the Hidden Potential of Current TB Drugs
Bryan J. Berube,
Infectious Disease Research Institute, USA
Short Talk: MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis Alone and in Combination with Electron-Transport Chain Inhibitors
Short Talk: MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis Alone and in Combination with Electron-Transport Chain Inhibitors
14:30—16:30
Workshop: Opportunities for Repurposing to Discover New Candidates or Mature Starting Points
*
Elnaz Menhaji-Klotz,
Bill & Melinda Gates Medical Research Institute, USA
*
Khisimuzi E. Mdluli,
Bill & Melinda Gates Medical Research Institute, USA
Oluyomi S. Adeyemi,
Landmark University, Nigeria
Drug Repurposing and Screening of Libraries of Chemical Compounds to Identify New Anti-Parasitic Agents
Drug Repurposing and Screening of Libraries of Chemical Compounds to Identify New Anti-Parasitic Agents
Samuel Arnold,
University of Washington, USA
A Second Chance for Your Favorite Protozoan Target: Repositioning Opportunities for Treatment of Cryptosporidosis
A Second Chance for Your Favorite Protozoan Target: Repositioning Opportunities for Treatment of Cryptosporidosis
Giancarlo Biagini,
Liverpool School of Tropical Medicine, UK
Antimalarial Pharmacology of Primaquine: Attempting to Solve a 70-Year-Old Puzzle
Antimalarial Pharmacology of Primaquine: Attempting to Solve a 70-Year-Old Puzzle
Elena Fernandez Alvaro,
GlaxoSmithKline, Spain
Repurposing Opportunities for the Treatment of MDR Bacterial Enteric Infections
Repurposing Opportunities for the Treatment of MDR Bacterial Enteric Infections
Malkeet Kumar,
University of Cape Town, South Africa
Repositioning the Antihistamine Drug Astemizole as an Anti-Plasmodial Agent
Repositioning the Antihistamine Drug Astemizole as an Anti-Plasmodial Agent
Rob Leurs,
Vrije Universiteit Amsterdam, Netherlands
Parasite-Specific Cyclic Nucleotide Phosphodiesterase Inhibitors to Target Neglected Parasitic Diseases (PDE4NPD)
Parasite-Specific Cyclic Nucleotide Phosphodiesterase Inhibitors to Target Neglected Parasitic Diseases (PDE4NPD)
Rose C. Lopeman,
Aston University, UK
Faropenem and Clavulanate Exhibit Additive Effect against Mycobacterium abscessus in vitro
Faropenem and Clavulanate Exhibit Additive Effect against Mycobacterium abscessus in vitro
17:00—18:45
Translational Tools for Predicting Efficacy and Resistance
Meeting has ended...abstracts no longer viewable online.
*
Robert S. Wallis,
Aurum Institute, South Africa
Wesley C. Van Voorhis,
University of Washington, USA
Pharmacodynamic Modeling of Anti-Cryptosporidium Drug Efficacy
Pharmacodynamic Modeling of Anti-Cryptosporidium Drug Efficacy
Yingda L. Xie,
NIAID, National Institutes of Health, USA
Improving Phase 2a TB Drug Development Models through PET/CT Imaging (NexGen EBA)
Improving Phase 2a TB Drug Development Models through PET/CT Imaging (NexGen EBA)
Cristina Donini,
Medicines for Malaria Venture, Switzerland
Role of Volunteer Infection Studies in Prioritizing the Next Generation of Clinical Candidates in Malaria
Role of Volunteer Infection Studies in Prioritizing the Next Generation of Clinical Candidates in Malaria
Thomas Spangenberg,
Merck, Switzerland
Short Talk: Evaluation of the Pharmacokinetic-Pharmacodynamic Relationship of Praziquantel in the Schistosoma mansoni Mouse Model
Short Talk: Evaluation of the Pharmacokinetic-Pharmacodynamic Relationship of Praziquantel in the Schistosoma mansoni Mouse Model
18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.
*Session Chair †Invited, not yet responded.
Keystone Symposia thanks our Sponsor for generously supporting this meeting:
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
